FENC vs GSK · rev $17.9M vs P/E 13, $103.31B cap
Fennec Pharmaceuticals Inc (FENC) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Fennec Pharmaceuticals Inc (FENC) is a biotechnology company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported FENC revenue for 2026-06-30 was $17.9M. Net income was $2.0M. Revenue was up 18.3% from 2026-03-31 to 2026-06-30. FENC currently screens at market cap $302.2M.
GSK does not have a complete income-statement cache yet.
FENC currently screens at market cap $302.2M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the FENC and GSK stock pages for the full models.
Not investment advice.